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Abstract
Background: The incidence and correlates of breast milk HIV-1 RNA detection were determined in intensively sampled
women receiving highly active antiretroviral therapy (HAART) for the prevention of mother-to-child HIV-1 transmission.
Methods: Women initiated HAART at 34 weeks of pregnancy. Breast milk was collected every 2–5 days during 1 month
postpartum for measurements of cell-associated HIV DNA and cell-free HIV RNA. Plasma and breast milk were also collected
at 2 weeks, 1, 3 and 6 months for concurrent HIV-1 RNA and DNA measurements. Regression was used to identify cofactors
for breast milk HIV-1 RNA detection.
Results: Of 259 breast milk specimens from 25 women receiving HAART, 34 had detectable HIV-1 RNA (13%, incidence 1.4
episodes/100 person-days 95% CI=0.97–1.9). Fourteen of 25 (56%) women had detectable breast milk HIV-1 RNA [mean 2.5
log10 copies/ml (range 2.0–3.9)] at least once. HIV-1 DNA was consistently detected in breast milk cells despite HAART, and
increased slowly over time, at a rate of approximately 1 copy/10
6 cells per day (p=0.02). Baseline CD4, plasma viral load,
HAART duration, and frequency of breast problems were similar in women with and without detectable breast milk HIV-1
RNA. Women with detectable breast milk HIV-1 RNA were more likely to be primiparous than women without (36% vs 0%,
p=0.05). Plasma HIV-1 RNA detection (OR=9.0, 95%CI=1.8–44) and plasma HIV-1 RNA levels (OR=12, 95% CI=2.5–56)
were strongly associated with concurrent detection of breast milk HIV-1 RNA. However, no association was found between
breast milk HIV-1 DNA level and concurrent breast milk HIV-1 RNA detection (OR=0.96, 95%CI=0.54–1.7).
Conclusions: The majority of women on HAART had episodic detection of breast milk HIV-1 RNA. Breast milk HIV-1 RNA
detection was associated with systemic viral burden rather than breast milk HIV-1 DNA.
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Introduction
Both HIV-1 cell-free RNA and cell-associated DNA are
associated with the risk of breast milk transmission [1,2,3]. In
the absence of antiretroviral therapy, HIV-1 RNA levels in the
breast milk are typically 1–2 log lower than in blood, and a
proportion of women have no detectable breast milk HIV-1 RNA
[1,2,4,5]. HAART initiated during pregnancy significantly
decreases breast milk HIV-1 RNA levels and decreases transmis-
sion risk [6,7]. However, antiretroviral therapy has distinct effects
on cell-free and cell-associated virus in the breast milk. In two
separate clinical trials, women on HAART had significantly
decreased breast milk HIV-1 RNA but not DNA [4,6]. It has been
hypothesized that HAART results in the rapid clearance of HIV-
infected, activated CD4+ T cells, but has a smaller effect on the
reservoir of virus in resting monocytes; hence the clearance of
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29777infected CD4+ T cells during HAART could affect cell-free RNA
loads, but have an insignificant effect on overall HIV-1 cell-
associated DNA levels [4].
Episodic low-level plasma RNA viremia is not uncommon in
adults with stable viral suppression on HAART [8,9,10,11].
Episodic detection of plasma HIV-1 RNA may result from
fluctuations in adherence, drops in drug levels, emergence of
resistant virus, transient increases in immune activation, or
activation of latently infected cells [12,13]. Episodic detection of
breast milk HIV-1 RNA has been described in antiretroviral naı ¨ve
women and women receiving single-dose nevirapine [1,14] but to
our knowledge, has not been studied in women receiving HAART.
Since HAART for PMTCT does not offer complete protection
from transmission during breastfeeding [15,16,17], it is plausible
that incomplete viral suppression in breast milk may have
significance for transmission at a population level. As rapidly
evolving guidelines and expanding programs will increase
numbers of women receiving HAART during breastfeeding,
defining determinants of breast milk HIV-1 breakthrough during
HAART may contribute to further strategic improvements in
PMTCT interventions. In this study among women with collection
of breast milk at frequent intervals (every 2–5 days) we determined
the incidence, magnitude, and correlates of breast milk HIV-1
RNA detection among women starting HAART during pregnancy
for PMTCT, and developed longitudinal regression models
exploring the relationship between viral replication in different
biological compartments.
Methods
Study participants and follow-up
This is a retrospective study utilizing cryopreserved specimens
and repository data from a previously conducted randomized
clinical trial (NCT00167674). The trial was approved by the
Institutional Review Board (IRB) at the University of Washington
(Seattle, WA, USA) and the Ethics in Research Committee (ERC)
at Kenyatta National Hospital (Nairobi, Kenya) and all clinical
investigations were conducted according to the principles
expressed in the Declaration of Helsinki. All study participants
provided written, informed consent for study participation on
behalf of themselves and their infants. The primary data analysis,
methods of recruitment, randomization, and follow-up have been
described elsewhere [4,7]. In brief, pregnant women were
recruited from the Mathare North City Council Clinic in Nairobi,
Kenya and were invited to enroll if they were HIV-1 seropositive,
had hemoglobin $8 g/dl, had no previous exposure to antiret-
roviral medications, were $18 years of age, agreed to home visits,
and resided in the clinic catchment area. Women with CD4 counts
$200 and #500 cells/mm
3 (who were not HAART-eligible
according to contemporaneous guidelines) were randomized at
approximately 34 weeks gestation to HAART or short-course
antenatal zidovudine (ZDV) plus single-dose nevirapine (NVP) at
delivery. This current report is restricted to the subset of 25
women in the HAART arm; breast milk viral rebound in women
from the ZDV/NVP arm will be discussed in a separate report (S.
Holte, in preparation). Women in the HAART arm received
zidovudine, lamivudine and nevirapine from 34 weeks gestation
until 6 months after delivery.
Throughout follow-up, infants were screened for HIV-1 DNA
from dried blood spots as previously described [18]. Maternal
plasma was collected at 32 weeks gestation, delivery, 2 weeks
postpartum, then 1, 3 and 6 months after delivery. Breast milk was
collected 1 to 3 times a week over the first month postpartum by
peer counselors who visited the home and observed mothers
manually express milk from a single breast into a sterile container.
After the first month, breast milk was collected at the third and
sixth months postpartum. Between 5 and 40 ml of breast milk was
collected at each time point. CD4 counts were measured from
blood specimens using flow cytometry. HIV-1 plasma viral loads
were measured using the Gen-Probe assay (Gen-Probe Inc., San
Diego, CA, USA) as previously described [19], the limit of
detection for plasma samples was 200 copies/ml.
At each clinic visit (months 1, 3 and 6) the number of pills
dispensed was recorded and women brought in unused pills for
counting. Adherence was estimated for each drug as the
percentage of pills taken over each study visit interval, assuming
the women had taken their morning dose on clinic day (unless
reporting otherwise):
pills dispensed at last visit { pills returned at current visit ½  =
daily dose|days between visit ðÞ {1 ½ 
Measurement of breast milk HIV-1 RNA and DNA
The processing of breast milk samples in this study have been
described elsewhere [4]. In brief, breast milk samples were
centrifuged at 7106g for 20 minutes and the lipid layer was
discarded. The supernatant was frozen at 270uC. The cell pellet
was resuspended in freezing media (70% RPMI , 20% fetal calf
serum, and 10% DMSO) and stored in liquid nitrogen.
HIV-1 RNA was measured from 100 ml of breast milk
supernatant using the GenProbe assay, the lower limit of detection
for the breast milk specimens was 100 copies/ml.
Cell-associated DNA was extracted from 500 ml of breast milk
cell suspension using the QIAmp DNA mini kit (Qiagen, Valencia,
California) and HIV-1 pol and b-actin DNA were quantified using
real-time PCR as previously described [1,20]. The lower limit of
detection was 1 copy/reaction, HIV-1 DNA levels were
normalized to the number of cells tested (number of b-actin
copies).
Statistical analysis
StataSE version 11.1 (College Station, Texas) was used for all
analyses. Viral load measurements below the limit of detection
were recoded to the mid-point between zero and the limit of
detection for each assay. The Mann-Whitney U test was used to
make non-parametric comparisons between variables and the
independent t test was used for comparison of means. The
incidence of viral detection was calculated using Cox regression to
estimate the recurrent failure rate; data were censored at the end
of HAART or 180 days postpartum, whichever came first.
Generalized estimating equations (GEE) were used to estimate
changes in HIV-1 DNA load over time, and to examine
associations between breast milk and plasma loads in longitudinal
models. Models for continuous outcomes used the identity link and
Gaussian errors; models for dichotomous outcomes used the
logistic link and binomial errors. All regression models were
constructed using exchangeable correlation matrix and robust
standard errors. Because many assays were below the limit of
detection, breast milk HIV-1 RNA was modeled as a dichoto-
mized outcome (detected/not detected). Plasma RNA was
included as alternately a dichotomous (detected/not detected) or
continuous (viral load) covariate. Since few specimens had
undetectable HIV-1 DNA, this was included only as a continuous
variable. Because there were many unmatched breast milk cell –
supernatant pairs following month 1, modeling for breast milk
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two-tailed.
Results
Study population
Between November 2003–March 2005, 58 women were
enrolled in the randomized trial, of whom 30 were randomized
to receive HAART; 2 were lost prior to delivery, 2 experienced
stillbirths, and 1 discontinued HAART before delivery. The
current study focuses on the 25 women who continued taking
HAART through delivery and 6 months of lactation. At delivery,
median duration of HAART in the cohort was 36 days
(IQR=25–48).
A total of 353 breast milk HIV-1 RNA assays were conducted,
259 of which were obtained during HAART. In women who were
still lactating, plasma and breast milk specimens were also
collected after HAART (94 specimens) interruption for studies of
viral rebound (Holte, in preparation), and are not analyzed here.
Breast milk HIV-1 DNA was additionally measured longitudinally
during the first 3 months of follow-up in the subset of 17 women
that had breast milk cell samples available (168 measurements) [4].
Breast milk HIV-1 RNA detection and suppression in
women receiving HAART for PMTCT
Plasma HIV-1 RNA viral load declined rapidly after women
started HAART (Figure S1), but because of the relatively late start
of HAART, the majority of women in this study had detectable
plasma HIV-1 RNA at their first postpartum visit (19/25, 76%).
Of 259 breast milk specimens assessed during HAART, 34 had
detectable HIV-1 RNA (13%); the mean level of detectable HIV-1
RNA was 2.5 log10 copies/ml (6SD 0.58), and ranged from 2.0 to
3.9 log10 copies/ml. A total of 14 women (56%) had detection of
breast milk HIV-1 RNA at least once, and 11 women (44%) never
had detectable breast milk HIV-1 RNA (Figure 1). The majority of
women with detectable breast milk HIV-1 RNA had episodic
detection of virus (12 women, virus detected at less than half their
visits). Two women had detection of HIV-1 RNA at more than
half of their visits (M-605 and M-616).
The 25 women provided a total of 2509 person-days of follow-
up during the first 9 months postpartum. The incidence of breast
milk HIV-1 RNA detection overall was 1.4 episodes/100 person-
days [95%CI 0.97–1.9]. Among women with detectable HIV-1
RNA (1342 person-days of follow-up), the incidence of detectable
breast milk HIV-1 RNA was 2.5 episodes/100 person-days
[95%CI 1.8–3.5].
Suppression of breast milk HIV-1 RNA despite an active
breast milk cellular reservoir
Seventeen of 25 women had detectable cell associated HIV-1
DNA at one or more visits. Breast milk HIV-1 DNA was detected
at high levels despite HAART, and was found in both women with
undetectable (Figure 2a) and detectable (Figure 2b) breast milk
HIV-1 RNA. Generalized estimating equations (GEE) were used
to compare the level of breast milk HIV-1 DNA measured at HIV-
1 RNA detectable and undetectable time-points (Figure 2c).
Overall, the level of breast milk HIV-1 DNA increased over time,
as previously described [4], at a rate of ,1 copy/10
6 cells per day
[slope=1.041, 95%CI=1.0073–1.076, p=0.02]. We observed no
difference in breast milk HIV-1 DNA load measured at HIV-1
RNA detectable and undetectable time-points; both the rate of
increase (p=0.99) and level (p=0.98) of HIV-1 DNA were
similar.
Comparison of women with detectable and
undetectable breast milk cell-free HIV-1 RNA detection
Obstetric, immunologic, and virologic characteristics were
compared between women with detectable and undetectable
breast milk HIV-1 RNA (Table 1). Women in the two groups were
similar in their duration of HAART at delivery, pre-HAART
disease status, gestational age at HAART initiation, delivery
plasma viral loads and CD4 counts, and adherence. Availability of
the participant, ability to express breast milk at discrete visits, and
confidentiality concerns during home visits resulted in some
women having more breast milk specimens collected than others.
There was no difference in the follow-up time or the number of
visits assessed between the two groups, and they also breastfed for
a similar duration of time. Women with detectable breast milk
HIV-1 RNA were more likely to be first-time mothers than
women with undetectable breast milk HIV-1 RNA; 36% (5/14) of
women with detectable breast milk HIV-1 RNA and none (0/11)
of the women with undetectable breast milk HIV-1 RNA were
primiparous (p=0.05). There was a trend for women with
detectable breast milk HIV-1 RNA to be younger than women
with undetectable breast milk HIV-1 RNA (26, IQR 25–30 versus
29 years, IQR 22–28; p=0.08, respectively). As expected,
primiparous women were also younger in age (data not shown),
suggesting age confounds the relationship between primiparity and
detection of breast milk HIV-1 RNA.
We collected detailed clinical data (self-report and clinical
examination) during follow-up. However, women were generally
well at enrollment, and we did not have adequate cases to detect
associations between intercurrent illness and detection of RNA in
milk/plasma (data not shown). There was 1 case of smear-positive
malaria, and this woman had detectable breast milk RNA, and
undetectable plasma RNA at the visit. Breast infections or breast
problems were not increased in women with detectable breast milk
HIV-1 RNA; three cases of clinical mastitis were identified and
only one of these had detectable breast milk HIV-1 RNA (p=0.6).
Overall, the frequency of clinically apparent breast problems was
similar between women with detectable (50%, 7/14) and
undetectable (45%, 5/11; p=1.0) breast milk HIV-1 RNA.
Breast milk HIV-1 RNA detection is strongly associated
with concurrent plasma RNA but not breast milk DNA
Generalized estimating equations (GEE) were used to determine
the association between systemic (plasma RNA) and local (breast
milk cell-associated DNA) HIV-1 replication and breast milk HIV-1
RNA(Table2)duringHAART.DetectionofHIV-1RNAinplasma
was associated with a 9-fold increased odds [95% CI=1.8–44] of
detecting HIV-1 RNA in the concurrently collected breast milk
specimen. The level of plasma RNA was also strongly correlated
with the detection of breast milk HIV-1 RNA (OR=12,
95%CI=2.5–56). Duration on HAART was not significantly
associated with breast milk HIV-1 RNA detection (p=0.5).
Interestingly, we did not find any association between the level
of breast milk HIV-1 DNA and breast milk HIV-1 RNA detection
(OR=0.96, 95%CI=0.54–1.7). Because breast milk HIV-1 DNA
levels increased and plasma RNA levels declined over time, we
also adjusted for days on HAART. Adjusting for HAART
duration did not change relationships observed in unadjusted
models; no association was observed between breast milk HIV-1
DNA levels and breast milk HIV-1 RNA detection (adjusted OR
(aOR)=1.0, 95%CI=0.56–1.8). Plasma RNA detection
(aOR=9.0, 95%CI=1.8–44) and plasma RNA load (aOR=13,
95%CI=2.0–92) remained significant predictors of breast milk
HIV-1 RNA detection.
HIV RNA in Breast Milk during PMTCT HAART
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e29777Figure 1. Detection of breast milk HIV-1 RNA in women receiving HAART for PMTCT. The detection of HIV-1 RNA is shown for 25 women
on HAART postpartum. Visits were ranked by date, and are shown only for visits while HAART was being administered. *The first postpartum HIV-1
plasma RNA measurement is provided for each woman. M-586 and -538 did not have a plasma viral load measured within a week of delivery; plasma
viral loads shown for these two women coincide with visit 1.
doi:10.1371/journal.pone.0029777.g001
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29777Finally, we performed a sensitivity analysis to determine
whether a few high level viral loads were driving the observed
associations, excluding breast milk HIV-1 RNA loads of $250
copies/ml. There were only 5 breast milk HIV-1 RNA loads $250
copies/ml that had concurrent plasma RNA load measurements;
exclusion of these 5 higher-level breast milk HIV-1 RNA load
measurements did not change any of the relationships observed in
either the univariate or multivariate models (Table 2), indicating
the associations observed in these models were not the result of a
small number of high level measurements.
Discussion
Maternal antiretroviral therapy is an effective intervention to
prevent breast milk HIV-1 transmission. In this study we evaluated
breast milk at frequent intervals 2–3 times weekly for cell-free and
Table 1. Comparison of women by detection of breast milk HIV-1 RNA.
Breast milk HIV-1 RNA
Never detected
Ever
detected P
(N=11) (N=14)
Sampling and follow-up
Number of follow-up visits 11 (10–11) 11 (10–11) 0.4
Days on HAART at delivery 35 (26–53) 37 (25–42) 0.8
Days of postpartum follow-up on HAART 92 (89–122) 92 (88–93) 0.5
Obstetric
Age (years) 29 (25–30) 26 (22–28) 0.08
Gravidity 2 (1–2) 1 (0–3) 0.4
Parity 1 (1–2) 1 (0–2) 0.3
Primiparous 0% (0/11) 36% (5/14) 0.05
Breastfeeding and breast problems
Duration of breastfeeding in days 182 (155–184) 182 (153–186) 0.8
Clinical mastitis
* 18% (2/11) 7.1% (1/14) 0.6
Cracked nipples
* 36% (4/11) 29% (4/14) 1.0
Any breast problem
** 45% (5/11) 50% (7/14) 1.0
Baseline HIV disease pre-HAART
HIV-1 log10 RNA copies/ml plasma VL 4.8 (4.6–4.9) 4.9 (4.7–5.0) 0.7
CD4 count (cells/mm
3) 279 (257–351) 280 (248–421) 0.8
HAART administration and adherence
Days on HAART at delivery 35 (26–53) 37 (25–42) 0.8
Combivir adherence (% pills taken) 96% (94–97) 96% (95–99) 0.9
Nevirapine adherence (% pills taken) 97% (95–99) 97% (95–100) 0.7
Total adherence (% pills taken) 97% (96–98) 96% (95–100) 1.0
Immunologic & virologic status at delivery
***
CD4 count (cells/mm
3) 445 (412–591) 385 (287–497) 0.3
HIV-1 log10 RNA copies/ml plasma VL 2.4 (2.0–2.8) 2.7 (2.5–2.9) 0.3
Plasma RNA detectable 73% (8/11) 79% (11/14) 0.5
Notes. Median (IQR) or frequency (n/N) are shown for each correlate. VL, viral load; p-d, person-days 95%CI, 95% confidence interval;
*At any time (includes antenatal and on HAART).
**Includes clinical mastitis, cracked nipples, localized swelling, and breast abscess.
***Measurements at delivery or first postpartum visit.
doi:10.1371/journal.pone.0029777.t001
Figure 2. Breast milk HIV-1 RNA, cell-associated DNA, and plasma RNA viral loads during HAART for PMTCT. Breast milk HIV-1 RNA
(solid line), breast milk HIV-1 DNA (dashed line), and plasma RNA (red line) are shown for women with a) suppression of HIV-1 RNA in breast milk and
b) detection of HIV-1 RNA in breast milk. All women with cell-associated virus measured are shown. *M-546 and -616 stopped HAART before 100 days;
arrows show last date HAART dispensed for these two women. Data points marked with an ‘‘x’’ indicate the measurement taken was at or below the
assay limit of detection. c) Scatter plot shows levels of breast milk HIV-1 DNA at breast milk HIV-1 RNA detectable (solid circles and solid line) and
undetectable (open circles and dashed line) time-points during HAART. Linear models are fit to the data. Data shown are limited to the first month
postpartum, because the majority of HIV-1 DNA measurements (154/163) were collected during this time interval.
doi:10.1371/journal.pone.0029777.g002
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more than half of the women receiving HAART, and women with
breast milk HIV-1 RNA detection were more likely to be
primiparous. The detection of breast milk HIV-1 RNA was
strongly associated with concurrent plasma RNA detection and
quantity. Consistent with previous reports [4,6], we observed no
association between breast milk HIV-1 RNA and breast milk
HIV-1 DNA. Since breast milk HIV-1 RNA loads were closely
related to plasma viral replication we infer that starting HAART
earlier would result in better systemic suppression by delivery, and
subsequently enable more complete suppression of HIV-1 RNA in
breast milk.
Though the majority (87%) of breast milk specimens in this
study had undetectable levels of HIV-1 RNA, 56% of women
receiving HAART for PMTCT had at least one episode of
detection. Most women had transient detection of breast milk
HIV-1 RNA but two (8%) had detection at more than half their
visits. In some clinical trials of breastfeeding women receiving
PMTCT HAART, transmission rates have been as low as ,2%
[15,16,17,21,22]. Both cell-associated and cell-free virus could
have significance for breast milk HIV-1 transmission [1,2,3]. The
high efficacy of HAART in reducing transmissions supports cell-
free RNA as the major contributor to transmission; the residual
transmission risk observed in these studies despite HAART could
be explained by episodic emergence of free virions in the milk
(HIV-1 RNA), or persistence of the viral reservoir in breast milk
cells (HIV-1 DNA).
In order to better understand mechanisms underlying episodic
breast milk HIV-1 RNA detection during HAART, we studied
relationships between viral replication in the blood and breast milk
compartments. We found a strong correlation between breast milk
HIV-1 RNA detection and both the detection and level of HIV-1
plasma RNA. In contrast, we did not find any association between
breast milk HIV-1 RNA detection and breast milk HIV-1 DNA
level. These data are consistent with findings from Shapiro and
colleagues who reported no correlation between breast milk
cellular DNA level and whole milk HIV-1 RNA levels at 2–5
months postpartum in women receiving ZDV plus single-dose
NVP [6].
Our finding that breast milk viral levels are more closely related
to plasma virus levels is also consistent with two recent
phylogenetic studies conducted in Malawi [23] and Zambia
[24], both of which found evidence for substantial mixing of
plasma and breast milk viral RNA sequences, and ongoing seeding
of the milk by viruses from the blood. The temporal correlation of
intermittent viremia in these two compartments suggests that virus
likely moves rapidly between these tissues, with viral breakthrough
in the blood being rapidly reflected by breakthrough in the breast
milk. Our data suggests that during the early weeks of HAART
initiated for PMTCT, episodic breast milk viremia is governed
more by movement of virus from the plasma than by local
replication of virus in breast milk cells.
The episodic detection of plasma viremia during suppressive
HAART has been interpreted as either viral breakthrough or false
positive assays [8,9,10,11]. The highly significant and large
association between plasma and breast milk HIV-1 RNA detection
we observed suggests that episodic detection of breast milk RNA in
women starting HAART for PMTCT is not due to a random
distribution of false-positive assays. Our sensitivity analysis further
supports the validity of these measurements, since the association
between HIV-1 RNA and plasma RNA was maintained when
excluding the few higher-level measurements.
In this study, baseline immunosuppression or plasma HIV-1
RNA, time on HAART, response to HAART, or adherence did
not differ significantly between women with and without breast
milk HIV-1 RNA detection. Primiparity was associated with the
detection of HIV-1 RNA in breast milk, which could imply
breastfeeding technique, breast physiology, or mastitis might play
a role in local HIV-1 reactivation. More study is needed to
confirm this finding and determine the biologic mechanism
explaining this association.
In this cohort, more than 70% of women had detectable low-
level (median 2.7 log10 RNA copies/ml) plasma HIV-1 RNA at
delivery. It is important to note that since women had been on
HAART for only ,5 weeks at delivery, the high frequency of
women with plasma viremia does not indicate treatment failure.
The 2010 WHO guidelines recommend initiation of HAART by
14 weeks gestation [25] and adults starting HAART are expected
achieve viral suppression to ,50 copies/ml within 16–24 weeks of
therapy (MMWR 51-RR07). The degree of viral suppression in
this cohort is consistent with data from other pregnancy cohorts,
which report 42–96% of women starting HAART earlier in the
Table 2. Predictors of concurrent HIV-1 cell-free RNA detection in breast milk during PMTCT HAART.
N Unadjusted OR [95% CI] Adjusted for time on HAART aOR [95% CI]
All assays
Days on HAART 25 1.0 [0.99–1.0], p=0.5
Plasma HIV-1 RNA level 24 12 [2.5–56], p=0.002 13 [2.0–92], p=0.008
Plasma HIV-1 RNA detected 24 9.0 [1.8–44], p=0.007 9.0 [1.8–44], p=0.007
Breast milk HIV-1 DNA level
* 17 0.96 [0.54–1.7], p=0.9 1.0 [0.56–1.8], p=1.0
Assays ,250 copies/ml breast milk HIV-1 RNA
**
Days on HAART 25 1.0 [0.98–1.0], p=1.0
Plasma HIV-1 RNA level 22 14 [3.1–59], p,0.001 18 [2.7–124], p=0.003
Plasma HIV-1 RNA detected 22 12 [1.3–115], p=0.03 12 [1.3–114], p=0.03
Breast milk HIV-1 DNA level
* 17 1.0 [0.48–2.1], p=1.0 1.0 [0.48–2.2], p=0.9
Notes. N, number of subjects in analysis. The association between breast milk HIV-1 RNA detection and each covariate is examined separately in an unadjusted model,
and adjusted for days on HAART.
*Analysis for breast milk HIV-1 DNA was restricted to the first month postpartum because the majority of HIV-1 DNA measurements (154/163) were made during this
time interval.
**In all models adjusted for time, days on HAART remained insignificant with an OR of approximately 1.0 (not shown).
doi:10.1371/journal.pone.0029777.t002
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The lower rate of suppression in our study may reflect differences
in adherence of women starting later in pregnancy, the restricted
CD4 eligibility criteria, and the relatively high viral load of women
in our cohort.
Strengths of our study include frequent sampling of breast milk
in the first month postpartum and the concurrent measurement of
cell-free and cell-associated virus. Limitations include imprecision
in measuring adherence; the time interval was different between
breast milk collection and adherence assessment, which makes it
difficult to determine whether temporal variations in adherence
explain episodes of breast milk HIV-1 RNA detection. Breast milk
HIV DNA measurements were not available for all women,
because many specimens collected after 1 month postpartum did
not contain adequate cell numbers for cryopreservation. As
previously reported, there were no breast milk HIV-1 transmis-
sions in the cohort, so we were not able to evaluate the relevance
of breast milk HIV-1 RNA on transmission [7]. Selection of
women with a narrow range of CD4 counts, and initiation of
HAART relatively late in gestation also limits generalizability of
these findings. Most women in the study initiated HAART during
their third trimester; since there was little variability in time on
HAART, we were not powered to examine the effect of HAART
duration on HIV-1 RNA detection.
In summary, breast milk HIV-1 RNA was commonly detected
in Kenyan women who had started HAART late in pregnancy
and was associated with systemic HIV-1 replication, but not local
breast milk HIV-1 DNA. These data suggest that plasma viral
suppression may be a marker for HIV-1 transmission risk during
pregnancy, and that earlier HAART may help reduce early
breastfeeding transmission risk. The lack of association between
HAART and breast milk HIV-1 DNA levels challenges the role of
cell-associated virus in breast milk transmission. Whether episodic
breast milk HIV-1 RNA or cell-associated DNA are responsible
for the very low rates of transmission in women on HAART for
PMTCT remains an open question requiring further study.
Supporting Information
Figure S1 Maternal virologic response to HAART.
Individual trajectories for plasma viral load during HAART are
shown by gray lines. Black lines show linear models fit to plasma
viral loads in antenatal (solid line) and postpartum (dashed line)
visits.
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